Staff

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform

Study demonstrated device functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE)...

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

error: Content is protected !!